In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Best of The IN VIVO Blog (02/2010)

Executive Summary

A selection of our favorite blog posts from January 2010 about stories not covered elsewhere in this issue of IN VIVO. (See the original postings for free at

You may also be interested in...

Biopharma Trends: Nowhere To Go But Up

Biopharmaceutical trends in 2008 were fundamentally altered by the global financial crisis. And 2009's events were similarly impacted by the ongoing recovery. VCs hunkered down as capital and exits remained scarce, and pharmaceutical acquirers remained cautious.Those deals that did get done were typically structured affairs or options-to-deal. In addition, health care reform added to the ongoing drama and uncertainty

Corporate Venture Capital: Will It Remain A Mainstay If The Markets Improve?

An analysis of corporate venture investment since the beginning of 2008.

Victoza Outperforms Byetta In Head-To-Head Trial

Head-to-head trial results presented at the American Diabetes Association meeting are positive, but safety questions aren't likely to go away.

Related Content

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts